Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2012 May 3;119(18):4108-14. doi: 10.1182/blood-2012-01-394411. Epub 2012 Mar 12.

How we choose factor VIII to treat hemophilia.

Author information

1
Scientific Direction, Department of Medicine and Medical Specialties, Istituto di Ricovero eCura a Carattere Scientifico Cá Granda Maggiore Policlinico Hospital Foundation, Milan, Italy. pmmannucci@libero.it

Abstract

In high-income countries, the large availability of coagulation factors for replacement therapy of patients with hemophilia A has raised the life expectancy of these lifelong bleeders to that of males from the general population. The practicing clinician is offered a multitude of choices among several commercial brands of factor VIII extracted from human plasma or engineered from mammalian cell cultures by means of recombinant DNA technology. This article has the goal to offer our opinions on how to choose among the different products, that we consider interchangeable relevant to their clinical efficacy in the control of bleeding and safety from pathogen transmission. Hence, the main determinants of our choices are price and the risk of occurrence of factor VIII inhibitory alloantibodies. With this as background, we present the rationale underlying the choices for different categories of patients with severe hemophilia A: previously untreated patients, multiply treated patients, and patients undergoing immune tolerance induction with large doses of factor VIII to eradicate inhibitors. Mention is also made to the possible strategies that should be implemented to make available coagulation factors for replacement therapy in developing countries.

PMID:
22411872
DOI:
10.1182/blood-2012-01-394411
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center